ABOUT ICBCC

A multi-stakeholder coalition consisting of representatives from the global patient advocacy and clinical community has formed the International COVID-19 Blood Cancer Coalition (ICBCC) to address the specific impact of COVID-19 on immunocompromised blood cancer patients (both acute and chronic), like those living with Chronic Lymphocytic Leukemia (CLL) and other Non-Hodgkin lymphomas (NHLs).

The Joint Patient Impact Statements and the campaign toolkits and educational materials that the coalition has been releasing since its initiation have been focusing on the changing landscape of the COVID-19 health crisis and has been supporting patients, clinicians, researchers, policy-makers, and the general public with tools and recommendations.

With COVID-19 having become a less severe problem for most populations, some groups like the immunocompromised blood cancer patients remain at elevated risk with some profound effects on their lives, forcing the ICBCC to constant shifts in approach and messaging.

The CLL Advocates Network (CLLAN) is acting as secretariat on behalf of the coalition.

In February 2022, the coalition released its first Joint Patient Impact Statement which focused on recommendations for governments and health authorities and was developed for use in different countries to aid when advocating for the provision of anti-COVID-19 treatment and care for immunocompromised (IC) blood cancer patients. Following on from this previous version, end of May 2023 the coalition released a revised statement. This latest version of the ICBCC Joint Patient Impact Statement discusses helping patients help themselves so they can re-engage with the world.

The Statement has been endorsed by more than 70 researchers, clinicians, patient organisations and medical societies.

To learn more about ICBCC´s latest activities and its presence at different congresses and meetings, please visit the LATEST NEWS section!